Zobrazeno 1 - 3
of 3
pro vyhledávání: '"929"'
Autor:
Ludwig H; Wilhelminen Cancer Research Institute, Wilhelminenhospital, Vienna, Austria. heinz.ludwig.lud@extern.wienkav.at., Moreau P; University of Nantes, Nantes, France., Dimopoulos MA; National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Mateos MV; University Hospital Salamanca, Salamanca, Spain., Kaiser M; The Institute of Cancer Research, London, UK., Hajek R; University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Feng S; Amgen Inc, Thousand Oaks, CA, USA., Cocks K; KCStats Consultancy, Leeds, UK., Buchanan J; Amgen Inc, Thousand Oaks, CA, USA., Weisel K; Universitatsklinikum Tubingen, Tubingen, Germany.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2019 Feb 22; Vol. 9 (3), pp. 23. Date of Electronic Publication: 2019 Feb 22.
Publikováno v:
Blood Cancer Journal; 5/16/2023, Vol. 13 Issue 1, p1-15, 15p
Autor:
Roman Hájek, Katja Weisel, Heinz Ludwig, Kim Cocks, Philippe Moreau, Martin Kaiser, Jaqueline Buchanan, Meletios A. Dimopoulos, Maria-Victoria Mateos, Shibao Feng
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 3, Pp 1-13 (2019)
Blood Cancer Journal, Vol 9, Iss 3, Pp 1-13 (2019)
We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European